14.12.2012Algeta’s partner Bayer submits New Drug Application to US FDA for Radium-223 Dichloride Press Release
12.12.2012Algeta’s partner Bayer submits Radium-223 Dichloride for EU Marketing Authorisation
Submission to trigger €50 million milestone payment to Algeta
Press Release05.09.2012F2G Ltd Completes $30 Million Financing Round to Fund Pre-clinical and Clinical Development of Novel Anti-fungal Compounds
Antifungal drug discovery and development company announces the completion of a $30 million equity financing round
Press Release20.07.2012First gene therapy in Western world receives positive opinion in Europe from CHMPPress Release
10.07.2012Advent Life Sciences Fund I Receives Additional Investments
Final Fund Size of £101.3 Million ($158 Million)
Press Release27.06.2012Advent Life Sciences Announces Appointment of Alain Huriez as Venture Partner Press Release
10.06.2012Need a light? It’s okay, I’ll just plug it in
Matthew Goodman from the Sunday Times explores the growth in electronic cigarettes
In The News30.05.2012CN CREATIVE ADVANCES REGULATORY INITIATIVES FOR ITS NICADEX™ AND INTELLICIG®
MANCHESTER, UK, May 30, 2012 – CN Creative, Ltd. (CNC), a healthcare company providing innovative and sustainable solutions to reduce smoking and smoking-related illnesses, today reported advances in the company’s regulatory and market initiatives for its Nicadex™ electronic inhaler nicotine replacement therapy (NRT) product and Intellicig® electronic cigarettes.
Press Release